XM ඇමරිකා එක්සත් ජනපදයේ පදිංචිකරුවන්ට සේවා සැපයීම සිදු නොකරයි.

XM ඇමරිකා එක්සත් ජනපදයේ පදිංචිකරුවන්ට සේවා සැපයීම සිදු නොකරයි.
B
B

Biogen

පුවත්

Reuters - දින 6කට පෙර

Brainy efforts underway, but still some way to go for neuro drug developers

LIVE MARKETS-Brainy efforts underway, but still some way to go for neuro drug developers Main U.S. indexes sharply higher; Nasdaq, Dow up 1.3% Cons Disc leads S&P sector gainers; Utilities sole loser Euro STOXX 600 index up 1.3% Dollar rises; gold edges up; crude, up >1%, bitcoin up 0.4% U.S. 10-Year Treasury yield edges up to ~4.33% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters.
A
B
R
U
U
Reuters - සති 1කට පෙර

U.S. Altair Engineering, Brinker International, Meta

U.S. RESEARCH ROUNDUP-Altair Engineering, Brinker International, Meta Oct 31 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Altair Engineering, Brinker International and Meta, on Thursday. HIGHLIGHTS * Altair Engineering Inc ALTR.O : Needham cuts to hold from buy * Blackbaud Inc BLKB.O : Baird cuts to neutral from outperform * Brinker International Inc EAT.N : JP Morgan cuts to neutral from overweight * Comstock Res
A
A
B
B
C
C
E
G
I
M
S
V
V
A
A
C
K
E
C
Reuters - සති 1කට පෙර

Biogen Inc reports results for the quarter ended in September 30 - Earnings Summary

Biogen Inc reports results for the quarter ended in September 30 - Earnings Summary Biogen Inc BIIB.OQ reported quarterly adjusted earnings of $4.08​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of $4.36. The mean expectation of twenty nine analysts for the quarter was for earnings of $3.79 per share.
B
Reuters - සති 1කට පෙර

Biogen lifts annual profit forecast as new treatments boost earnings

UPDATE 2-Biogen lifts annual profit forecast as new treatments boost earnings Updates shares, adds analyst comment in paragraph 4, CEO comment in paragraph 7 and graphic By Mariam Sunny Oct 30 (Reuters) - Biogen BIIB.O raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of its multiple sclerosis drugs.
B
N
Reuters - සති 1කට පෙර

Biogen Q3 Adjusted EPS USD 4.08 Vs. IBES Estimate USD 3.79

BRIEF-Biogen Q3 Adjusted EPS USD 4.08 Vs. IBES Estimate USD 3.79 Oct 30 (Reuters) - Biogen Q3 revenue USD 2,500 million vs. IBES estimate USD 2,434 million. Q3 EPS USD 2.66
B
Reuters - සති 1කට පෙර

Biogen Says Still Sees FY Rev Down Low-Single Digit Percent, With Core Pharma Rev Roughly Flat

BRIEF-Biogen Says Still Sees FY Rev Down Low-Single Digit Percent, With Core Pharma Rev Roughly Flat Oct 30 (Reuters) - Biogen Inc BIIB.O : BIOGEN Q3 ADJUSTED EPS $4.08 VERSUS IBES ESTIMATE $3.79 BIOGEN OUTLOOK FY ADJUSTED EPS $16.10 TO $16.60 VERSUS PRIOR OUTLOOK $15.75 TO $16.25 BIOGEN FY2024 EPS VIEW $16.19, REVENUE VIEW $9.64 BILLION -- IBES DA
B
Reuters - සති 1කට පෙර

Biogen lifts annual profit forecast as cost cuts help

Biogen lifts annual profit forecast as cost cuts help Oct 30 (Reuters) - Biogen BIIB.O raised annual profit forecast and beat third-quarter profit expectations on Wednesday, as its cost-cutting measures helped make up for falling sales of its multiple sclerosis medicines. The drugmaker has cut jobs and pulled the plug on less promising drug candidates in a series of cost-saving measures, focusing on higher-growth products as CEO Christopher Viehbacher takes the lead to bring the cash-strapped bi
B
Reuters - සති 1කට පෙර

Alphabet beats and Treasuries rally

MORNING BID AMERICAS-Alphabet beats and Treasuries rally A look at the day ahead in U.S. and global markets from Mike Dolan Markets struggling which way to look will be dizzy again in an event-strewn Wednesday but the spotlight first thing drops on Alphabet's GOOGL.O impressive earnings beat and a relief-rally in election-bruised U.S. Treasuries. A critical fortnight for investors includes next week's U.S.
A
B
B
C
E
G
G
I
M
M
P
U
U
V
V
A
A
K
J
U
U
U
U
G
I
P
Reuters - සති 1කට පෙර

Biogen And Neomorph Announce Multi-Target Research Collaboration To Discover And Develop Molecular Glue Degraders For Alzheimer’S, Rare, And Immunological Diseases

BRIEF-Biogen And Neomorph Announce Multi-Target Research Collaboration To Discover And Develop Molecular Glue Degraders For Alzheimer’S, Rare, And Immunological Diseases Oct 29 (Reuters) - Biogen Inc BIIB.O : BIOGEN AND NEOMORPH ANNOUNCE MULTI-TARGET RESEARCH COLLABORATION TO DISCOVER AND DEVELOP MOLECULAR GLUE DEGRADERS FOR ALZHEIMER’S, RARE,
B
Reuters - සති 1කට පෙර

What to Watch in the Day Ahead - Wednesday, October 30

What to Watch in the Day Ahead - Wednesday, October 30 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT On the U.S. economic front, the Commerce Department's Bureau of Economic Analysis' advance estimate of the gross domestic product (GDP) is expected to show that the economy grew at a 3% pace i
B
C
M
S
V
K
K
C
Reuters - සති 1කට පෙර

Gradual dosing of Lilly Alzheimer's drug cuts brain-swelling risk, study finds

Gradual dosing of Lilly Alzheimer's drug cuts brain-swelling risk, study finds  By Julie Steenhuysen CHICAGO, Oct 29 (Reuters) - Starting on a more gradual dosing schedule of Eli Lilly's LLY.N Alzheimer's drug Kisunla cut the percentage of patients experiencing potentially serious brain swelling, according to interim results of a late-stage trial presented at a medical meeting on Tuesday.
B
Reuters - සති 1කට පෙර

Biogen Appoints Daniel Quirk, MD, As Chief Medical Officer

BRIEF-Biogen Appoints Daniel Quirk, MD, As Chief Medical Officer Oct 29 (Reuters) - Biogen Inc BIIB.O : BIOGEN APPOINTS DANIEL QUIRK, MD, AS CHIEF MEDICAL OFFICER Source text: ID:nGNX7Mg1HF Further company coverage: BIIB.O
B
Reuters - සති 1කට පෙර

Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial

Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial By Bhanvi Satija and Christy Santhosh Oct 29 (Reuters) - Coya Therapeutics COYA.O said on Tuesday its experimental Alzheimer's drug was safe and increased levels of a type of immune cells that help prevent neuroinflammation in patients with Alzheimer's disease enrolled in a small, mid-stage trial.
B
Reuters - සති 2කට පෙර

Michael Mcdonnell, Executive Vice President And Chief Financial Officer To Retire In February 2025

BRIEF-Michael Mcdonnell, Executive Vice President And Chief Financial Officer To Retire In February 2025 Oct 28 (Reuters) - Biogen Inc BIIB.O : MICHAEL MCDONNELL, EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER TO RETIRE IN FEBRUARY 2025 BIOGEN INC - ROBIN KRAMER TO SUCCEED MICHAEL MCDONNELL AS BIOGEN CFO Source text: ID:nGNX6xGqF2 Further com
B
Reuters - සති 2කට පෙර

Biogen appoints insider as CFO after Michael McDonnell to retire next year

UPDATE 2-Biogen appoints insider as CFO after Michael McDonnell to retire next year Adds background in paragraph 3, details on Kramer in paragraph 6 Oct 28 (Reuters) - Biogen BIIB.O said on Monday insider Robin Kramer will take over as the drugmaker's finance chief after incumbent Michael McDonnell retires at the end of February next year. The appointment of Kramer, who joined Biogen in 2018 and currently serves as its chief accounting officer, comes at a time when the company is aiming for a tu
B
Reuters - සති 2කට පෙර

Biogen CFO Michael McDonnell to retire

Biogen CFO Michael McDonnell to retire Oct 28 (Reuters) - Biogen BIIB.O said on Monday Chief Financial Officer Michael McDonnell plans to retire on Feb. 28, 2025. Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar
B
Reuters - සති 2කට පෙර

AbbVie banks on Alzheimer's therapy with $1.4 billion buy of Aliada

UPDATE 4-AbbVie banks on Alzheimer's therapy with $1.4 billion buy of Aliada Rewrites 1-5 paragraphs to add background, competition Oct 28 (Reuters) - U.S. drugmaker AbbVie ABBV.N said on Monday it will buy Aliada Therapeutics for $1.4 billion in cash, betting on an experimental Alzheimer's treatment still in the early stage of development. AbbVie, with a market value of about a $330 billion, squared off against at least three other pharmaceutical companies interested in Aliada, a person familia
B
Reuters - සති 2කට පෙර

Biogen Presents Positive Results From Phase 2 Ignaz Study Of Felzartamab In Iga Nephropathy At American Society Of Nephrology (Asn) Kidney Week 2024

BRIEF-Biogen Presents Positive Results From Phase 2 Ignaz Study Of Felzartamab In Iga Nephropathy At American Society Of Nephrology (Asn) Kidney Week 2024 Oct 26 (Reuters) - Biogen Inc BIIB.O : BIOGEN PRESENTS POSITIVE RESULTS FROM PHASE 2 IGNAZ STUDY OF FELZARTAMAB IN IGA NEPHROPATHY AT AMERICAN SOCIETY OF NEPHROLOGY (ASN) KIDNEY WEEK 2024 BIOGEN
B
Reuters - සති 2කට පෙර

What to Watch in the Week Ahead and on Monday, October 28

What to Watch in the Week Ahead and on Monday, October 28 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT ON MONDAY Ford is expected to report higher third-quarter revenue and profit, aided by sales of its commercial vehicles.
A
A
B
C
C
C
C
D
G
I
J
M
P
P
R
S
K
K
E
R
U
Reuters - සති 2කට පෙර

UK approves Lilly's Alzheimer's drug, but deemed 'too expensive' for wide use

UPDATE 4-UK approves Lilly's Alzheimer's drug, but deemed 'too expensive' for wide use Adds Lilly's statement in paragraph 6 and background on EU decision in paragraph 10 Oct 23 (Reuters) - Eli Lilly's LLY.N treatment for early Alzheimer's was deemed too expensive for wide use by UK's cost-effectiveness body on Wednesday, signalling that patients are unlikely to get access following approval by the country's medicines regulator.
B

තත්ත්වයන්

ජනප්‍රිය වත්කම්

වියාචනය: XM Group සමාගම් ක්‍රියාත්මක කිරීම පමණක් වන සේවා සපයන අතර වෙබ් අඩවියේ හෝ වෙබ් අඩවිය හරහා ලබා ගත හැකි අන්තර්ගතය බැලීමට සහ/හෝ භාවිත කිරීමට පුද්ගලයෙකුට ඉඩ සලසමින් අපගේ මාර්ගගත වෙළඳ පහසුකම වෙත ප්‍රවේශය ලබා දෙන අතර වෙනස් කිරීමට හෝ පුළුල් කිරීමට අදහස් නොකරයි. එවැනි ප්‍රවේශය සහ භාවිතය සෑම විටම (i) නියමයන් සහ කොන්දේසි, (ii) අවදානම් අනතුරු ඇඟවීම් සහ (iii) සම්පූර්ණ වියාචනයට යටත් වේ. එබැවින් එවැනි අන්තර්ගතයක් සාමාන්‍ය තොරතුරුවලට වඩා වැඩි යමක් සපයා නොමැත. විශේෂයෙන්ම, අපගේ මාර්ගගත වෙළඳ පහසුකමේ අන්තර්ගතය පෙළඹවීමක් හෝ මූල්‍ය වෙළඳපොළවල කිසිදු ගනුදෙනුවක් සිදු කිරීමට ඉදිරිපත් කිරීමක් නොවන බව කරුණාවෙන් සලකන්න. ඕනෑම මූල්‍ය වෙළඳපොළක වෙළඳාම් කිරීම ඔබේ ප්‍රාග්ධනයට සැලකිය යුතු අවදානමක් එක් කරයි.

අපගේ මාර්ගගත වෙළඳ පහසුකමේ ප්‍රකාශිත සියලු කරුණු අධ්‍යාපනික/තොරතුරුමය අරමුණු සඳහා පමණක් අදහස් කෙරෙන අතර මූල්‍ය, ආයෝජන බදු හෝ වෙළඳ උපදෙස් සහ නිර්දේශයන්; හෝ අපගේ වෙළඳ මිල පිළිබඳ වාර්තාවක්; හෝ ඕනෑම මූල්‍ය උපකරණයක ඉදිරිපත් කිරීමක් හෝ ඒ සඳහා පෙළඹවීමක්; හෝ විශේෂ ඉල්ලීමකින් තොරව ඔබ වෙත ලබා දෙන ලද මූල්‍ය ප්‍රවර්ධනයන් ලෙස නොසැලකිය යුතුය.

ඕනෑම තෙවන පාර්ශවීය අන්තර්ගතයක් මෙන්ම XM විසින් සකසන ලද අන්තර්ගතය එනම් අදහස්, පුවත්, පර්යේෂණ, විශ්ලේෂණ, මිල ගණන් සහ වෙනත් තොරතුරු හෝ මෙම වෙබ් අඩවියේ අන්තර්ගත තෙවන පාර්ශවීය වෙබ් අඩවි සඳහා සබැඳි සාමාන්‍ය වෙළඳපොළ විවරණයක් ලෙස "පවතින පරිදි" සපයා ඇති අතර එහි ආයෝජන උපදෙස් ඇතුළත් නොවේ. ඕනෑම අන්තර්ගතයක් ආයෝජන පර්යේෂණයක් ලෙස අර්ථ දක්වා ඇති ප්‍රමාණයට, ආයෝජන පර්යේෂණයේ ස්වාධීනත්වය ප්‍රවර්ධනය කිරීමට නිර්මාණය කර ඇති නෛතික අවශ්‍යතාවලට අනුකූලව අන්තර්ගතය සකසා නොමැති බවත් එලෙස අරමුණු කර නොමැති බවත් ඔබ සලකා පිළිගත යුතු අතර එබැවින් එය අදාළ නීති සහ රෙගුලාසි යටතේ අලෙවිකරණ සන්නිවේදනයක් ලෙස සලකනු ලැබේ. ඉහත සඳහන් තොරතුරු සලකා මෙතනින් ප්‍රවේශ විය හැකි, ස්වාධීන නොවන ආයෝජන පර්යේෂණ සහ අවදානම් අනතුරු ඇඟවීම පිළිබඳ අපගේ දැනුම්දීම ඔබ කියවා තේරුම් ගෙන ඇති බව සහතික කර ගන්න.

අවදානම් අනතුරු ඇඟවීම: ඔබේ ප්‍රාග්ධනය අවදානමේ පවතී. උත්තෝලිත (ලෙවරේජ්) නිෂ්පාදන සෑම දෙනාටම සුදුසු නොවිය හැකිය. කරුණාකර අපගේ අවදානම් අනාවරණය සලකා බලන්න.